LONDON, Sept 7 (Reuters) - Roche (ROG.VX) boosted its early-stage central nervous system (CNS) drug pipeline on Tuesday by signing a drug development deal for new Parkinson’s and Alzheimer’s disease medicines with Belgium’s reMYND.
LONDON, Sept 7 (Reuters) - Roche (ROG.VX) boosted its early-stage central nervous system (CNS) drug pipeline on Tuesday by signing a drug development deal for new Parkinson’s and Alzheimer’s disease medicines with Belgium’s reMYND.
